CD | UC | |
---|---|---|
Patients number (n = 112) | 84 | 28 |
Males/females | 39/45 (46%/54%) | 11/17 (39%/60%) |
Mean age at TDM (SD) | 36 years (10.9) | 35 years (11.2) |
Mean duration of adalimumab therapy (SD) | 157.8 weeks (101.7) | 70.1 weeks (58.0) |
Age at onset (<16y/17-40y/>40y) | 13/64/7 | - |
Localisation of Crohn’s disease (ileal/colon/ileocolon/upper GI/ileocolon + upper GI) | 13/16/47/2/5 | - |
Extension of colitis (proctitis/left sided/extensive) | - | 0/19/9 |
Behaviour of CD (inflammatory/stricturing/penetrating/strict. + pen.) | 29/18/27/10 | - |
Perianal disease in CD | 42/84 (50%) | - |
Previous surgery | 43/84 (48.8%) | 0/28 (0%) |
Smoking (yes/no/previous) | 44/24/16 | 19/2/7 |
Previous 5-ASA | 69/84 (82.1%) | 26/28 (93%) |
Previous steroid | 76/84 (90.5%) | 28/28 (100%) |
Previous/concomitant AZA | 67/84 (80%)/42/84 (50%) | 20/28 (71.4%)/2/28 (28.6%) |
Previous anti-TNF | 50/84 (60.2%) | 23/28 (82%) |
Previous IFX/ADM/both | 38/5/7 | 22/1/0 |